Last reviewed · How we verify
NCT07195825
A Clinical Study to Evaluate the Safety, and Tolerability of BBM-P002 in the Treatment of Parkinson's Disease
Phase 1 trial testing Injecting BBM-P002 into the bilateral putamen in PD in 18 participants. Currently enrolling.
30 December 2027
Quick facts
| Lead sponsor | Shanghai Xinzhi BioMed Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 18 |
| Start date | 27 December 2025 |
| Primary completion | 30 December 2027 |
| Estimated completion | 30 December 2031 |
| Sites | 1 location across China |
Drugs / interventions tested
- Injecting BBM-P002 into the bilateral putamen
Conditions studied
- PD — all drugs for PD →
Sponsor
Shanghai Xinzhi BioMed Co., Ltd. — full company profile →
Who can join
Adults 40 to 70, any sex, with PD. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of the study is to evaluate the safety and tolerability of BBM-P002 for stereotactic injection to treat participants with idiopathic Parkinson's Disease (PD) during the dose-limiting toxicity (DLT) observation period.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07195825
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Shanghai Xinzhi BioMed Co., Ltd. trials
Trials by the same sponsor.
- NCT06111638 — Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs · Phase 2, PHASE3 · recruiting
- NCT05203679 — Evaluation of the Safety and Efficacy of Hemophilia B Gene Therapy Drug · Phase 2, PHASE3 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07195825 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Xinzhi BioMed Co., Ltd.
- Last refreshed: 28 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07195825.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing